Skip to main content

Table 1 Subject characteristics

From: Impact of smoking on dendritic cell phenotypes in the airway lumen of patients with COPD

  Control group (C) n = 10 COPD total group (T) n = 24 COPD current smoker (S) n = 13 COPD former smoker (F) n = 11 C-T p C-S p C-F p S-F p
Age (years) 51.0 [40…68] 55.0 [35…73] 52.0 [35…63] 62.0 [38…73] 0.491 0.879 0.132 0.055
Gender (m / f) 6 / 4 18 / 6 10 / 3 8 / 3 NA NA NA NA
BMI (kg*m−2) 25.6 [23.2…36.9] 24.5 [18.7…39.0] 23.0 [18.7…37.4] 31.1 [23.5…39.0] 0.360 0.021 0.426 0.007
Pack years 0.0 [0…0] 34.0 [10…60] 40.0 [15…60] 32.0 [10…50] <0.001 <0.001 <0.001 0.284
Medication LABA without ICS/LABA plus ICS/LAMA 0 / 0 / 0 3 / 10 / 10 0 / 5 / 4 3 / 5 / 6 NA NA NA NA
FEV 1 (% pred.) 114.3 [93.9…126.6] 63.6 [41.5…80.0] 65.2 [41.5…80.0] 62.0 [51.5…71.4] <0.001 <0.001 <0.001 0.392
IVC (% pred.) 107.1 [82.6…116.8] 86.7 [29.3…114.4] 83.6 [29.3…114.4] 88.8 [35.2…97.9] 0.008 0.115 0.002 0.608
FEV 1 % FVC (%) 82.5 [77.2…98.3] 60.5 [34.4…71.5] 60.5 [34.4…71.5] 60.5 [47.4…66.8] <0.001 <0.001 <0.001 0.955
MEF50 (% pred.) 98.0 [72.2…156.2] 24.5 [11.7…39.4] 24.7 [11.7…39.4] 22.6 [16.9…32.0] <0.001 <0.001 <0.001 0.649
RV (% pred.) 91.0 [79.6…136.0] 136.1 [87.1…185.4] 129.7 [115.3…185.4] 136.2 [87.1…183.8] <0.001 <0.001 0.001 0.569
TLC (% pred.) 100.5 [85.8…121.5] 102.7 [86.1…148.9] 101.0 [89.3…148.9] 106.0 [86.1…127.0] 0.669 0.738 0.705 0.955
Hemoglobin (mmol/l) 9.2 [7.3…10.3] 9.1 [7.1…11.3] 9.3 [7.1…11.3] 8.9 [8.0…9.7] 0.809 0.832 0.468 0.531
Hematocrit (%) 43.0 [38.0…49.0] 44.0 [38…52] 45.0 [38.0…52.0] 41.0 [39.0…48.0] 0.897 0.605 0.756 0.691
Platelets (*109/l) 229 [180…320] 236 [155…374] 246 [155…374] 226 [165…331] 0.985 0.693 0.705 0.608
Leukocytes (*109/l) 5.9 [3.8…8.2] 7.5 [3.9…12.3] 7.7 [3.9…10.2] 7.3 [4.0…12.3] 0.101 0.077 0.314 0.955
CRP (mg/l) 1.1 [1.0…9.5] 2.1 [1.0…15.1] 1.9 [1.0…10.6] 2.3 [1.0…15.1] 0.170 0.446 0.099 0.459
  1. Shown are general characteristics of the subjects, results of pulmonary function tests and blood parameters. All patients treated with inhaled corticosteroids (ICS) were also treated with a long-acting beta-agonist (LABA) in a fixed combination (“LABA plus ICS”). Parameters are displayed as median values [minimum…maximum]. Abbreviations denote: c-reactive protein (CRP), Inspiratory vital capacity (IVC), Forced expiratory volume in the first one second (FEV1), ratio of the FEV1 to the forced vital capacity (FEV1/FVC), maximum expiratory flow at 50% of VC (MEF50), residual volume (RV), total lung capacity (TLC). The four columns on the right side of the table show comparisons between the groups: Control vs. total group of COPD patients (C-T), Control vs. COPD (current smoker) (C-S), Control vs. COPD (former smoker) (C-F) and COPD (current smoker) vs. COPD (former smoker) (S-F).